Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 4Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Pain 2Neoplasms 2Chronic Pain 1Agnosia 1

Interventions

Cyclophosphamide 389Carboplatin 343Gemcitabine 331pembrolizumab 328Cisplatin 327Paclitaxel 294Radiotherapy 291Docetaxel 285Bevacizumab 249Rituximab 233Capecitabine 221Nivolumab 218Dexamethasone 205Fluorouracil 189fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 133Bortezomib 129fludarabine phosphate 128Cetuximab 126Lenalidomide 125Filgrastim 119Erlotinib Hydrochloride 119Temozolomide 111Radiosurgery 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Interventional × Tapentadol × Clear all
NCT01264887 2019-11-04

Tapentadol in Chronic Malignant Tumour Related Pain

Grünenthal GmbH

Phase 3 Terminated
31 enrolled 19 charts

Agnosia, Neoplasms, Pain, Chronic Pain

NCT00505414 2019-11-01

A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine

Grünenthal GmbH

Phase 3 Terminated
136 enrolled 9 charts

Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡